Stocktoria
COLLEGIUM PHARMACEUTICAL, INC COLL
COLLEGIUM PHARMACEUTICAL, INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M | — | — |
| R&D expense | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M | $8.6M | $14.9M |
| SG&A expense | $284.8M | $210.4M | $159.2M | $172.2M | $119.0M | $113.8M | $116.4M | $126.8M | $92.8M | $80.6M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | -$23.7M | -$20.7M | -$75.4M | -$94.1M |
| Interest expense | — | — | $83.3M | $63.2M | $21.0M | $28.9M | $909,000 | $20.1M | — | $94,000 |
| Income tax | $29.7M | $29.4M | $27.6M | -$3.8M | -$74.9M | $830,000 | $0 | — | — | — |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | $71.5M | $26.8M | -$22.7M | -$39.1M | -$74.9M | -$94.2M |
| EPS (diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.68 | $-1.19 | — | — |
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M | $93.9M | $27.8M | $169.4M | -$67.0M | -$75.1M |
| Free cash flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M | $88.4M | $21.3M | $163.9M | -$68.0M | -$75.5M |
| Cash & equivalents | $231.3M | $70.6M | $238.9M | $173.7M | $186.4M | $174.1M | $170.0M | $146.6M | $118.7M | $153.2M |
| Inventory | $40.9M | $35.6M | $32.3M | $46.5M | $17.4M | $15.6M | $9.6M | $7.8M | $1.8M | $1.3M |
| Total assets | $1.7B | $1.7B | $1.1B | $1.2B | $692.1M | $643.8M | $306.3M | $291.2M | $135.6M | $162.0M |
| Total liabilities | $1.4B | $1.4B | $947.9M | $979.3M | $489.1M | $457.8M | $218.9M | $199.7M | $31.5M | $27.1M |
| Shareholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M | $186.0M | $87.4M | $91.6M | $104.1M | $134.9M |
Growth · year-over-year · Revenue CAGR 97.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +23.6% | +11.4% | +22.2% | +67.6% | -10.7% | +4.5% | +5.8% | +884.7% | +1564.3% | — |
| Net income growth | -9.1% | +43.7% | — | -135.0% | +167.3% | — | — | — | — | — |
| EPS growth | -7.0% | +44.2% | — | -139.8% | +144.7% | — | — | — | — | — |
| Free cash flow growth | +61.1% | -25.9% | +123.7% | +20.7% | +15.0% | +314.1% | -87.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.